GMAB Genmab

  1. Stocks
  2. Healthcare
  3. NASDAQ: GMAB

Price (delayed)

$28.87

Market cap

$18.55B

P/E Ratio

21.71

Dividend/share

N/A

EPS

$1.33

Enterprise value

$22.38B

?
Relative Growth: Rel. Growth: 76
Relative Strength: Rel. Strength: 49
Relative Valuation: Rel. Valuation: 47
Relative Profitability: Rel. Profitability: 87

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with ...

Highlights
Genmab's revenue has increased by 21% YoY and by 4.9% QoQ
The company's gross profit rose by 18% YoY and by 4.5% QoQ
The quick ratio has dropped by 60% year-on-year but it is up by 7% since the previous quarter
GMAB's price to earnings (P/E) is 37% higher than its last 4 quarters average of 15.8 but 32% lower than its 5-year quarterly average of 32.0
The net income has contracted by 28% YoY and by 15% from the previous quarter
The EPS has contracted by 25% YoY and by 14% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.genmab.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of GMAB

GMAB stock price

How has the Genmab stock price performed over time
Intraday
-1.03%
1 week
0.52%
1 month
11.62%
1 year
22.18%
YTD
-6.27%
QTD
5.1%

Financial performance

How have Genmab's revenue and profit performed over time
Revenue
$3.9B
Gross profit
$3.64B
Operating income
$1.06B
Net income
$821M
Gross margin
93.3%
Net margin
21%
Genmab's net margin has decreased by 40% YoY and by 19% from the previous quarter
The net income has contracted by 28% YoY and by 15% from the previous quarter
Genmab's revenue has increased by 21% YoY and by 4.9% QoQ
The company's gross profit rose by 18% YoY and by 4.5% QoQ

Price vs fundamentals

How does GMAB's price correlate with its fundamentals

Growth

What is Genmab's growth rate over time

Valuation

What is Genmab stock price valuation
GMAB P/E details
P/E
21.71
P/B
3.26
P/S
4.75
EV/EBIT
15.86
EV/EBITDA
14.97
EV/Sales
5.74
GMAB's price to earnings (P/E) is 37% higher than its last 4 quarters average of 15.8 but 32% lower than its 5-year quarterly average of 32.0
The EPS has contracted by 25% YoY and by 14% from the previous quarter
The P/B is 36% below the 5-year quarterly average of 5.1 but 5% above the last 4 quarters average of 3.1
The equity has grown by 7% YoY but it has contracted by 2.8% from the previous quarter
The P/S is 54% below the 5-year quarterly average of 10.3
Genmab's revenue has increased by 21% YoY and by 4.9% QoQ

Efficiency

How efficient is Genmab business performance
The ROA has plunged by 55% YoY and by 27% from the previous quarter
Genmab's return on invested capital has shrunk by 52% YoY and by 24% QoQ
Genmab's ROE has decreased by 39% YoY and by 17% from the previous quarter
The ROS has contracted by 28% YoY and by 9% from the previous quarter

Dividends

What is GMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GMAB.

Financial health

How did Genmab financials performed over time
The total assets is 85% greater than the total liabilities
The total assets has surged by 88% year-on-year but it has declined by 3.9% since the previous quarter
The quick ratio has dropped by 60% year-on-year but it is up by 7% since the previous quarter
Genmab's debt is 6% less than its equity
The equity has grown by 7% YoY but it has contracted by 2.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.